Non-small cell lung cancer. Palliative chemotherapy in stage IV non-small cell lung cancer and in patients with comorbidity

被引：0
作者：
M. Reck
K.M. Deppermann
U. Gatzemeier
N. Niederle
机构：
[1] Onkologischer Schwerpunkt, Krankenhaus Großhansdorf
[2] Klinik für Pneumologie, Ruppiner Kliniken
[3] Medizinische Klinik III, Klinikum Leverkusen
[4] Onkologischer Schwerpunkt, Krankenhaus Großhansdorf, 22927 Großhansdorf
来源：
Der Onkologe | 2006年 / 12卷 / 8期
关键词：
Chemotherapy; Comorbidity; Elderly patients; Non-small cell lung cancer; Second-line treatment;
D O I：
10.1007/s00761-006-1081-z
中图分类号：
学科分类号：
摘要：
Chemotherapy is a cornerstone in the treatment of metastatic non-small cell lung cancer due to the high frequency of metastatic stages at diagnosis. By introducing new drugs, the efficacy and tolerability of chemotherapy could be improved. Chemotherapy with a platinum based doublet containing a third generation drug for four to six cycles is standard in first-line treatment. Neither a three or four drug schedule, nor the application of more cycles could demonstrate any increase in efficacy. Patients with reduced performance status and elderly patients with comorbidity should receive monotherapy with gemcitabine, vinorelbine or taxanes. Elderly patients with a good performance status, however, might be candidates for a modified combination therapy. Pemetrexed, docetaxel and the EGFR inhibitor erlotinib are options as second-line treatment following progression or relapse. © Springer Medizin Verlag 2006.
引用
收藏
页码：761 / 768
页数：7
相关论文
共 53 条
[1]  
4. Überarbeitete und Aktualisierte Ausgabe, Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland, (2004)
[2]  
Mountain C.F., Revision in the the international system for staging of Lung Cancer, Chest, 111, pp. 1710-1717, (1997)
[3]  
A meta-analysis using updated data on individual patients from 52 randomised clinical trials, Br Med J, 311, pp. 899-909, (1995)
[4]  
Spiro S.G., Rudd R.M., Souhami R.L., Et al., Chemotherapy versus supportive care in advanced non-small cell lung cancer: Improved survival without detriment to quality of life, Thorax, 59, pp. 828-836, (2004)
[5]  
Rudd R.M., Gower N.H., Spiro S.G., Et al., Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIb or IV non-small cell lung cancer: A phase III randomized study of the London Lung Cancer Group, J Clin Oncol, 23, pp. 142-153, (2005)
[6]  
Crino L., Scagliotti G.V., Ricci F., Et al., Gemcitabine and Cisplatin versus Mitomycin, Ifosfamide and Cisplatin in advanced non-small cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project, J Clin Oncol, 17, pp. 3522-3530, (1999)
[7]  
Cardenal F., Lopez-Cabrerizo M.P., Anton A., Et al., Randomized phase III study of Gemcitabine-Cisplatin versus Etoposide-Cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer, J Clin Oncol, 17, pp. 12-18, (1999)
[8]  
Le Chevalier T., Brisgand D., Douillard J.Y., Et al., Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of an European multicenter trial including 612 patients, J Clin Oncol, 14, pp. 687-688, (1996)
[9]  
Le Chevalier T., Brisgand D., Soria J.C., Et al., Long term analysis of survival in the European randomized trial comparing Vinorelbine to Vindesine/ Cisplatin and Vinorelbine alone in advanced non-small cell lung cancer, Oncologist, 6, 1 SUPPL., pp. 8-11, (2001)
[10]  
Kubota K., Watanabe K., Kunitoh H., Et al., Phase III randomized trial of docetaxel plus cisplatin versus Vindesine plus cisplatin in patients with stage IV non-small cell lung cancer: The Japanese Taxotere Lung Cancer Study Group, J Clin Oncol, 22, pp. 254-261, (2004)
123456